Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis
- Authors: Kubanov A.A.1, Bakulev A.L.2, Samtsov A.V.3, Khairutdinov V.R.3, Sokolovskiy E.V.4, Kokhan M.M.5, Artemyeva A.V.6, Chernyaeva EV.6, Ivanov R.A.6
-
Affiliations:
- State Research Center of Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation
- Saratov State Medical University named after V. I. Razumovsky, Ministry of Health of the Russian Federation
- S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation
- Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation
- Ural Research Institute for Dermatovenerology and Immunopatology
- BIOCAD company
- Issue: Vol 95, No 2 (2019)
- Pages: 15-28
- Section: ORIGINAL STUDIES
- Submitted: 17.07.2019
- Accepted: 17.07.2019
- Published: 17.04.2019
- URL: https://vestnikdv.ru/jour/article/view/480
- DOI: https://doi.org/10.25208/0042-4609-2019-95-2-15-28
- ID: 480
Cite item